Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics (NASDAQ: GYRE), a commercial-stage biopharmaceutical company focused on fibrosis-first therapies, has appointed Dr. Dan Weng to its Board of Directors effective August 18, 2025.
Dr. Weng brings nearly 40 years of experience in managing global clinical trials and currently serves as President and CEO of Medelis, Inc. His extensive background includes executive positions at major CROs and research roles at prestigious institutions including Harvard Medical School and Massachusetts General Hospital.
The appointment comes at a strategic time as Gyre aims to expand its commercial reach and advance its multi-national pipeline. Dr. Weng's expertise in regulatory affairs and clinical trial management is expected to support the company's growth initiatives.
Gyre Therapeutics (NASDAQ: GYRE), azienda biofarmaceutica in fase commerciale focalizzata su terapie contro la fibrosi, ha nominato Dr. Dan Weng nel suo Consiglio di Amministrazione con efficacia dal 18 agosto 2025.
Il Dr. Weng porta con s茅 quasi 40 anni di esperienza nella gestione di studi clinici globali e ricopre attualmente la carica di Presidente e CEO di Medelis, Inc. Il suo percorso professionale comprende ruoli esecutivi in grandi CRO e attivit脿 di ricerca presso istituzioni di prestigio come la Harvard Medical School e il Massachusetts General Hospital.
La nomina arriva in un momento strategico, mentre Gyre punta a estendere la propria presenza commerciale e a far progredire il suo portafoglio multinazionale. L鈥檈sperienza del Dr. Weng in materia regolatoria e nella gestione di trial clinici 猫 destinata a sostenere le iniziative di crescita dell鈥檃zienda.
Gyre Therapeutics (NASDAQ: GYRE), una compa帽铆a biofarmac茅utica en fase comercial centrada en terapias para la fibrosis, ha nombrado a Dr. Dan Weng como miembro de su Junta Directiva con efecto a partir del 18 de agosto de 2025.
El Dr. Weng aporta casi 40 a帽os de experiencia en la gesti贸n de ensayos cl铆nicos globales y actualmente es Presidente y CEO de Medelis, Inc. Su amplia trayectoria incluye puestos ejecutivos en grandes CRO y labores de investigaci贸n en instituciones de prestigio como Harvard Medical School y Massachusetts General Hospital.
El nombramiento se produce en un momento estrat茅gico, mientras Gyre busca ampliar su alcance comercial y avanzar en su cartera multinacional. Se espera que la experiencia del Dr. Weng en asuntos regulatorios y gesti贸n de ensayos cl铆nicos respalde las iniciativas de crecimiento de la compa帽铆a.
Gyre Therapeutics (NASDAQ: GYRE)電� 靹湢頇� 旃橂鞐� 欤茧牓頃橂姅 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎� 旮办梾鞙茧, Dr. Dan Weng鞚� 2025雲� 8鞗� 18鞚茧秬搿� 鞚挫偓須� 鞚挫偓搿� 靹犾瀯頄堨姷雼堧嫟.
Weng 氚曥偓電� 鞝� 靹戈硠 鞛勳儊鞁滍棙 甏�毽� 攵勳暭鞐愳劀 瓯办潣 40雲勳潣 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅� 順勳灛 Medelis, Inc.鞚� 須岇灔 瓴� CEO搿� 鞛 欷戩瀰雼堧嫟. 攴胳潣 韽創鞚� 瓴诫牓鞐愲姅 欤检殧 CRO鞚� 瓴届榿歆� 歆侅眳瓿� 頃橂矂霌� 鞚橁臣雽�頃�(Harvard Medical School) 氚� 毵れ偓於旍劯旄� 膦呿暕氤戩洂(Massachusetts General Hospital) 霌� 鞝�氇� 旮瓣磤鞐愳劀鞚� 鞐瓣惮 頇滊彊鞚� 韽暔霅╇媹雼�.
鞚措矆 鞛勲獏鞚� Gyre臧� 靸侅梾鞝� 氩旍渼毳� 頇曥灔頃橁碃 雼り淡鞝� 韺岇澊頂勲澕鞚胳潉 歆勳爠鞁滍偆霠る姅 鞝勲灥鞝� 鞁滌爯鞐� 鞚措（鞏挫鞀惦媹雼�. Weng 氚曥偓鞚� 攴滌牅 氚� 鞛勳儊鞁滍棙 甏�毽� 鞝勲靹膘潃 須岇偓鞚� 靹膘灔 於旍鞚� 歆�鞗愴暊 瓴冹溂搿� 旮半寑霅╇媹雼�.
Gyre Therapeutics (NASDAQ: GYRE), soci茅t茅 biopharmaceutique en phase commerciale ax茅e sur des th茅rapies ciblant la fibrose, a nomm茅 Dr. Dan Weng au sein de son conseil d'administration, 脿 compter du 18 ao没t 2025.
Le Dr Weng apporte pr猫s de 40 ans d'exp茅rience dans la gestion d'essais cliniques 脿 l'茅chelle mondiale et occupe actuellement les fonctions de pr茅sident et CEO de Medelis, Inc. Son parcours comprend des postes de direction au sein de grandes CRO et des activit茅s de recherche dans des institutions prestigieuses telles que la Harvard Medical School et le Massachusetts General Hospital.
Cette nomination intervient 脿 un moment strat茅gique, alors que Gyre cherche 脿 茅tendre sa port茅e commerciale et 脿 faire progresser son portefeuille multinational. L'expertise du Dr Weng en mati猫re r茅glementaire et de gestion des essais cliniques devrait soutenir les initiatives de croissance de l'entreprise.
Gyre Therapeutics (NASDAQ: GYRE), ein kommerziell t盲tiges Biopharmaunternehmen mit Schwerpunkt auf fibroseorientierten Therapien, hat Dr. Dan Weng mit Wirkung zum 18. August 2025 in seinen Vorstand berufen.
Dr. Weng bringt nahezu 40 Jahre Erfahrung in der Leitung globaler klinischer Studien mit und ist derzeit Pr盲sident und CEO von Medelis, Inc. Zu seinem umfangreichen beruflichen Hintergrund z盲hlen F眉hrungspositionen bei gro脽en CROs sowie Forschungsaufenthalte an renommierten Institutionen wie der Harvard Medical School und dem Massachusetts General Hospital.
Die Berufung erfolgt zu einem strategischen Zeitpunkt, da Gyre seine kommerzielle Reichweite ausbauen und seine multi颅nationale Pipeline vorantreiben will. Dr. Wengs Expertise in regulatorischen Belangen und im Management klinischer Studien wird voraussichtlich die Wachstumsinitiativen des Unternehmens unterst眉tzen.
- Addition of seasoned executive with 40 years of clinical trial management experience
- Strategic appointment to support commercial expansion and pipeline advancement
- Strengthened board expertise in regulatory affairs and global clinical operations
- None.
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (鈥淕yre鈥�) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the 鈥淏oard鈥�) effective August 18, 2025.
Dr. Weng has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization (鈥淐RO鈥�), since 2018. From 2013 to 2017, he served as Chairman, President, and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global CRO where he oversaw significant growth, both organically and through M&A in Asia, and played an active role in corporate strategy and investor relations. Prior to that, Dr. Weng held executive positions at international CROs including MedPace, Inc., ICON Plc, PharmaNet Development Group, and Quintiles Translational Corp. Dr. Weng also held research positions at Harvard Medical School, Massachusetts General Hospital, and the University of California.
Dr. Weng holds an M.D. from the Tongji Medical University, and an M.A. in Health Planning, Policy and Management from the University of Leeds.
鈥淲e are pleased to welcome Dr. Weng to our Board at this pivotal time in Gyre鈥檚 evolution. Dan brings nearly four decades of experience in managing global clinical trials across a range of therapeutic areas,鈥� said Ping Zhang, Executive Chairman and Interim Chief Executive Officer of Gyre. 鈥淗is strategic insight and extensive regulatory experience will be invaluable as we continue to expand our commercial reach and advance our multi-national pipeline.鈥�
About Gyre Pharmaceuticals
Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY庐 (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2024 net sales of
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre鈥檚 strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People鈥檚 Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY庐, and development programs for F573, F528, and F230.
For Investors:
David Zhang
Gyre Therapeutics
[email protected]
FAQ
Who is Dan Weng and what is his role at Gyre Therapeutics (NASDAQ: GYRE)?
What is Dr. Dan Weng's professional background before joining Gyre Therapeutics' board?
How will Dr. Weng's appointment benefit Gyre Therapeutics?
What is Gyre Therapeutics' main business focus?
